Sotrovimab To Be Provided At Amarillo Infusion Center

The City of Amarillo has announced they will now be providing Sotrovimab to patients at the Amarillo Infusion Center.

This is due to a new direction from the Centers for Disease Control and Prevention and the Texas Department of State Health Services.

Sotrovimab will replace Bamlanivimab and Regeneron as treatment for Covid-19 patients who are eligible for treatment at the infusion center, located at 808 South Johnson Street.

The infusion center uses a prioritization method for treatment for the most vulnerable patients as supplies remain limited.

The City says Sotrovimab is deemed more effective against the Omicron variant.